IL33 and inflammatory bowel disease: Although ST2/IL33 axis neutralisation might represent an effective therapeutic target to control the inflammation that characterises IBD, new findings suggest that sST2 perpetuates inflammatory responses by restraining IL33-driven ST2+ Treg cell accumulation and function in the intestine15.